Usage of oral hypoglycemic agents
| Group | Drug class | Visit (year) | |
| Baseline | 3.0 | ||
| A | Patients | 3395 (100.0%) | 1839 (100.0%) |
| No use of oral hypoglycemic drugs | 0 (0.0%) | 48 (2.6%) | |
| Sulfonylureas | 1160 (34.2%) | 619 (33.7%) | |
| Rapid-acting insulin secretagogues | 100 (2.9%) | 128 (7.0%) | |
| α-Glucosidase inhibitors | 539 (15.9%) | 321 (17.5%) | |
| Biguanides | 1352 (39.8%) | 894 (48.6%) | |
| Thiazolidinediones | 508 (15.0%) | 325 (17.7%) | |
| DPP-4 inhibitors | 3395 (100.0%) | 1687 (91.7%) | |
| SGLT2 inhibitors | 1 (0.03%) | 160 (8.7%) | |
| B | Patients | 1755 (100.0%) | 965 (100.0%) |
| No use of oral hypoglycemic drugs | 0 (0.0%) | 35 (3.6%) | |
| Sulfonylureas | 505 (28.8%) | 235 (24.4%) | |
| Rapid-acting insulin secretagogues | 347 (19.8%) | 185 (19.2%) | |
| α-Glucosidase inhibitors | 435 (24.8%) | 215 (22.3%) | |
| Biguanides | 1192 (67.9%) | 622 (64.5%) | |
| Thiazolidinediones | 342 (19.5%) | 157 (16.3%) | |
| DPP-4 inhibitors | 0 (0.0%) | 352 (36.5%) | |
| SGLT2 inhibitors | 21 (1.2%) | 108 (11.2%) | |
DPP, dipeptidyl peptidase; SGLT, sodium-glucose cotransporter.